Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway
Metrics: PDF 953 views | HTML 1118 views | ?
Rajmohan Murali1,2, Raghu Chandramohan2, Inga Möller4, Simone L. Scholz5, Michael Berger1,2, Kety Huberman2, Agnes Viale2, Mono Pirun2, Nicholas D. Socci2, Nancy Bouvier2, Sebastian Bauer6, Monika Artl8, Bastian Schilling4, Tobias Schimming4, Antje Sucker4, Benjamin Schwindenhammer7, Florian Grabellus7, Michael R. Speicher8, Jörg Schaller10, Uwe Hillen4, Dirk Schadendorf4, Thomas Mentzel11, Donavan T. Cheng2, Thomas Wiesner3,9 and Klaus G. Griewank4
1 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York NY, USA
2 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York NY, USA
3 Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center, New York NY, USA
4 Department of Dermatology, UUniversity Hospital Essen, University of Duisburg-Essen, Essen, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany
5 Department of Ophthalmology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany
6 Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany
7 Institute of Pathology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany
8 Institute of Human Genetics, Medical University of Graz, Graz, Austria
9 Department of Dermatology, Medical University of Graz, Graz, Austria
10 Dermatopathology Duisburg, Duisburg, Germany
11 Dermatopathology Friedrichshafen, Friedrichshafen, Germany
Rajmohan Murali, email:
Thomas Wiesner, email:
Klaus G. Griewank, email:
Keywords: angiosarcoma, genetics, MAPK pathway, MYC
Received: August 10, 2015 Accepted: September 14, 2015 Published: September 30, 2015
Angiosarcomas are rare malignant mesenchymal tumors of endothelial differentiation. The clinical behavior is usually aggressive and the prognosis for patients with advanced disease is poor with no effective therapies. The genetic bases of these tumors have been partially revealed in recent studies reporting genetic alterations such as amplifications of MYC (primarily in radiation-associated angiosarcomas), inactivating mutations in PTPRB and R707Q hotspot mutations of PLCG1. Here, we performed a comprehensive genomic analysis of 34 angiosarcomas using a clinically-approved, hybridization-based targeted next-generation sequencing assay for 341 well-established oncogenes and tumor suppressor genes. Over half of the angiosarcomas (n = 18, 53%) harbored genetic alterations affecting the MAPK pathway, involving mutations in KRAS, HRAS, NRAS, BRAF, MAPK1 and NF1, or amplifications in MAPK1/CRKL, CRAF or BRAF. The most frequently detected genetic aberrations were mutations in TP53 in 12 tumors(35%) and losses of CDKN2A in9 tumors (26%). MYC amplifications were generally mutually exclusive of TP53 alterations and CDKN2A loss and were identified in 8 tumors (24%), most of which (n = 7, 88%) arose post-irradiation. Previously reported mutations in PTPRB (n = 10, 29%) and one (3%) PLCG1 R707Q mutation were also identified. Our results demonstrate that angiosarcomas are a genetically heterogeneous group of tumors, harboring a wide range of genetic alterations. The high frequency of genetic events affecting the MAPK pathway suggests that targeted therapies inhibiting MAPK signaling may be promising therapeutic avenues in patients with advanced angiosarcomas.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.